Kolexia
Hilgers Werner
Médecine interne
Institut Sainte Catherine
Avignon, France
65 Activités
199 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome pulmonaire non à petites cellules Tumeurs du poumon Carcinome pulmonaire à petites cellules Tumeurs de la prostate Carcinomes Tumeurs prostatiques résistantes à la castration Néphrocarcinome COVID-19 Tumeurs de la vessie urinaire

Industries

Janssen
26 collaboration(s)
Dernière en 2023
Ipsen
25 collaboration(s)
Dernière en 2023
AstraZeneca
23 collaboration(s)
Dernière en 2023
MSD
16 collaboration(s)
Dernière en 2023

Dernières activités

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.
Annals of oncology : official journal of the European Society for Medical Oncology   11 septembre 2023
MOIO: Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Metastatic Cancer in Response After 6 Months of Standard IO
Essai Clinique (Unicancer)   29 août 2023
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable): A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents
Essai Clinique (Bayer)   10 mai 2023
Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution between 2009 and 2020.
Cancers   30 mars 2023
Place à la santé N°2 : Le cancer de la prostate - Facebook
Facebook   28 novembre 2022
Étude de vraie vie d'utilisation du durvalumab en consolidation après radio-chimiothérapie dans les cancers bronchiques non à petites cellules (CBNPC) de stade III non résécables : cohorte française de PACIFIC-R
14e Colloque Données de santé en vie réelle   01 novembre 2022
L’intensification du traitement du cancer de la prostate métastatique hormonosensible (MHSPC) est devenue un standard de prise en charge en France (étude profile)
116e congrès français d'urologie   01 novembre 2022
1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
Quality of life (QoL) of OSE2101 in patients with HLA-A2+ non–small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial.
2022 ASCO Annual Meeting I   02 juin 2022